The present invention relates to a novel use of a PPAR δ agonist, and more particularly, to a fetal reprogramming effect of a PPAR δ agonist. According to the present invention, a PPAR δ agonist adjusts calcium ion during embryo genesis and a early fetal development period to increase slow muscle fiber and to thus improve muscle endurance, thereby improving lipid and glucose metabolism and reprogramming the metabolism of the entire body, thus preventing/inhibiting the occurrence of metabolic diseases, such as obesity and diabetes in an adult body caused by a high-fat diet and a lack of exercise, and improving memory for an adult. In addition, fetal reprogramming using a PPAR δ agonist prevents/inhibits the occurrence of diabetes in a mouse model for diabetes. Therefore, the PPAR δ agonist may be used in a pharmaceutical composition for enhancing the endurance of a human and an animal by embryonic/fetal reprogramming, preventing/inhibiting metabolic diseases such as obesity, diabetes, arteriosclerosis and fatty liver, and enhancing memory. The PPAR δ agonist may also be used in a nutritional supplement for pregnant women, in food additives, in a functional food supplement or functional beverage composition, in pharmaceutical compositions for animals, in an endurance enhancer for animals, in dry milk and baby formula compositions, in an animal feed composition, etc.La présente invention concerne une nouvelle utilisation d'un agoniste des PPAR δ et, plus particulièrement, un effet de reprogrammation fœtale d'un agoniste des PPAR δ. Selon la présente invention, un agoniste des PPAR δ ajuste l'ion calcium pendant la genèse de l'embryon et une période de développement fœtal précoce pour augmenter les fibres musculaires lentes et ainsi améliorer l'endurance musculaire, améliorant ainsi le métabolisme des lipides et du glucose et reprogrammant le métabolisme du corps entier, empêchant/inhibant ainsi l'occurrence de maladies métaboliques telles que l'obésité et le diabète da
